Evidence map›Paper›PMID 32292329›Full record

ArticleFrontiers in molecular neuroscience2020

NF-κB Inhibitors Attenuate MCAO Induced Neurodegeneration and Oxidative Stress-A Reprofiling Approach.

Awais Ali, Fawad Ali Shah, Alam Zeb, Imran Malik, Arooj Mohsin Alvi, Lina Tariq Alkury, Sajid Rashid, Ishtiaq Hussain, Najeeb Ullah, Arif Ullah Khan and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Frontiers in molecular neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. ALDH2 activation attenuates oxygen-glucose deprivation/reoxygenation-induced cell apoptosis, pyroptosis, ferroptosis and autophagy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  3. Article
  4. Article
  5. Pharmacological evaluation of carvacrol anti-migraine potential.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Effect ofFrontiers in pharmacology · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Awais AliRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Fawad Ali ShahRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Alam ZebRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Imran MalikRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Arooj Mohsin AlviRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Lina Tariq AlkuryCollege of Natural and Health Sciences, Zayed University, Abu Dhabi, United Arab Emirates.
Sajid RashidNational Center for Bioinformatics, Quaid-i-Azam University, Islamabad, Pakistan.
Ishtiaq HussainDepartment of Pharmacy, Abbottabad University of Science and Technology, Khyber Pakhtunkhwa, Pakistan.
Najeeb UllahInstitute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.
Arif Ullah KhanRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Phil Ok KohDepartment of Anatomy, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Shupeng LiState Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen, China.
Riphah International University · PKAbbottabad University of Science and Technology · PKCentre for Addiction and Mental Health · CAGyeongsang National University · KRPeking University · CNQuaid-i-Azam University · PKZayed University · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is the leading cause of morbidity and mortality worldwide. About 87% of stroke cases are ischemic, which disrupt the physiological activity of the brain, thus leading to a series of complex pathophysiological events. Despite decades of research on neuroprotectants to probe for suitable therapies against ischemic stroke, no successful results have been obtained, and new alternative approaches are urgently required in order to combat this pathological torment. To address these problems, drug repositioning/reprofiling is explored extensively. Drug repurposing aims to identify new uses for already established drugs, and this makes it an attractive commercial strategy. Nuclear factor-kappa beta (NF-κB) is reported to be involved in many physiological and pathological conditions, such as neurodegeneration, neuroinflammation, and ischemia/reperfusion (I/R) injury. In this study, we examined the neuroprotective effects of atorvastatin, cephalexin, and mycophenolate against the NF-κB in ischemic stroke, as compared to the standard NF-κB inhibitor caeffic acid phenethyl ester (CAPE). An in-silico docking analysis was performed and their potential neuroprotective activities in the

Indexed as

atorvastatincaeffic acid phenethyl estercephalexinMCAO strokemycophenolatep-NF-κBreprofiling

Identifiers

PMID32292329
PMCPMC7121334
OpenAlexW3013116734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.